electroCore Expands Intellectual Property Portfolio
- None.
- None.
The issuance of two new U.S. patents to electroCore, Inc. signifies a strategic enhancement of the company's intellectual property portfolio, specifically in the field of bioelectronic medicine. The patents pertain to non-invasive vagus nerve stimulation (nVNS) technology, which is an emerging area in medical treatment. The patents cover innovations in remote therapy and patient monitoring, as well as medical devices designed for specific dosing protocols. This development is particularly relevant to medical professionals and companies in the bioelectronic and neuromodulation sectors.
From a medical research perspective, the ability to monitor heart rate variability (HRV) as a response to nVNS therapy could lead to personalized treatment regimens, potentially improving patient outcomes. The second patent's focus on dosage control could minimize risks of overstimulation and enhance patient safety. These advancements might also streamline the regulatory approval process for new therapies, as they demonstrate a commitment to patient-specific treatment parameters and safety considerations.
In terms of market impact, patents are critical assets that can provide competitive advantages. For stakeholders, such as investors and partners, these patents could indicate electroCore's potential for sustained market exclusivity and the ability to fend off competition. This is particularly important in the high-growth market of bioelectronic medicine, where technological differentiation is key to standing out. The patents may also open doors for licensing opportunities, collaborations and further innovations within the company's pipeline.
However, the real-world impact of these patents will depend on the commercial viability of the nVNS technology, market adoption rates and the outcomes of any ongoing or future clinical trials. It is also important to consider the speed at which competitors are advancing their technologies and the overall patent landscape, which could influence electroCore's market position and the technology's lifecycle.
From a financial perspective, the announcement of new patents is often viewed positively by the market as it suggests potential for future revenue streams and growth. The patents could lead to an increase in the company's valuation due to the anticipated protection of its technology and the potential for new product developments. It's also essential to monitor the company's R&D expenditures and how these patents might influence its financial roadmap.
Investors should consider the scalability of the patented technology, the size of the addressable market and the company's ability to commercialize its patents effectively. While patents are an indicator of innovation, they do not guarantee commercial success; therefore, evaluating the company's track record in bringing products to market and securing regulatory approvals is also crucial.
electroCore Granted Two New U.S. Patents
ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on December 26, 2023, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
- US Patent No. 11,850,056 entitled “Devices and Methods for Remote Therapy and Patient Monitoring” generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a heart rate variability (HRV) of the patient, and comparing the HRV with data related to parameters of the therapy regimen.
- US Patent No. 11,854,695 entitled “Medical Devices for Treating Medical Conditions" generally relates to a medical device that includes a signal generator for applying electrical impulses to the patient for a period of time (i.e., a single dose), wherein the device is configured to deactivate upon a first occurrence of a specific number of single doses being applied to the patient or a specific time elapsing after the first dose is applied.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What company has been granted two new U.S. patents related to non-invasive vagus nerve stimulation (nVNS) technology?
What are the patent numbers for the two new U.S. patents granted to electroCore, Inc. (Nasdaq: ECOR)?
What is the focus of US Patent No. 11,850,056 granted to electroCore, Inc. (Nasdaq: ECOR)?
What is the focus of US Patent No. 11,854,695 granted to electroCore, Inc. (Nasdaq: ECOR)?
